Aims: Better documentation of vulvar pain is needed. We examined pain locations marked on general body and genital specific outlines among women with vulvodynia. Methods: 62 women (mean age 32.1 ± 9.5 years) with vulvodynia marked their pain on a digital genital specific outline (22 segments) and 59 of those women also marked their pain on a digital general body outline (48 segments). We used ImageJ software to determine body surface area (BSA) for each outline. Results: On the general body outline, 24/48 segments were marked; 22/22 segments were marked on the genital specific outline. There was a moderate correlation ( r = 0.43; p = 0.001) between the BSA marked on the general body outline and the BSA marked on the genital area outline. Conclusions: Findings support concurrent validity of the BSA as a measure of pain location using either outline.

Introduction: Pancreatic cancer (PC) is currently the third-leading cause of cancer deaths in the United States. African Americans with PC have an increased incidence and worse survival outcome when compared to other racial groups. During the COVID-19 pandemic, there is evidence that hospital resources were allocated to treating immediate life-threatening conditions. Some of the daily highest case numbers were reported in the state of Florida with several peaks throughout 2020 and 2021. Additionally, the state of Florida has the second-highest rate of new cases of PC within the United States with an incidence of 4860/100,000. Our specific aim is to define the impact of COVID-19 between race, age, income, and gender on the survival time of newly diagnosed patients with pancreatic cancer in Florida. Materials and Methods: Patients with pancreatic adenocarcinoma diagnosed from January 1st, 2017 to October 31st, 2020 were identified through the statewide clinical research and network database called OneFlorida Clinical Consortium by using the ICD10 diagnosis code for pancreatic cancer. Patients were then placed into 3 cohorts based on date of pancreatic cancer diagnosis: pre-pandemic (01/01/2017- 09/30/2019), transition (10/01/2019-02/28/2020), and pandemic (03/1/2020-10/31/2020). Patients with a diagnosis of neuroendocrine carcinoma were excluded. Patients were followed for at least one year unless a death occurred. Summary statistics were reported for demographic variables (age, sex, income, gender). Kaplan-Meier analysis with log-rank test was performed to compare the difference in overall survival time among groups. Results: This retrospective study had a total of 934 unique patients available for analysis. Of the 934 patients, 81.3% were in the pre-pandemic cohort (n= 759), 8.2% transition cohort (n=77), and 10.5% pandemic cohort (n=98). There was a decrease in the rate of diagnosis from the pre-pandemic (23 per month) to pandemic cohort (12.2 per month). The demographic distribution of the sample was 23.4% Black, 68.7% White and 7.9% Other. The median age was 67 years (27–89). There were 49.8% women and 50.2% men. The median income was $52,915 ($23,704–$124,821). The differences in overall survival time were not significant for age and gender across the 3 cohorts. Income <$53,000 had significantly lower survival time across the 3 cohorts. African Americans had significantly lower survival time for pre-pandemic and transition cohort (p< .005), but Caucasians had the lowest survival time for the pandemic cohort (p <.005). When stratified for stage, the mean survival (in months) for White vs. Black populations was 37.8 vs. 26.1 for stage I, 37.6 vs. 27.3 for stage II, 28.5 vs.18.77 for stage III, and 20.7 vs. 21.7 for stage IV. Discussion: This study demonstrated a decrease in diagnosis & survival rate during the COVID-19 pandemic in Florida. Dissemination of resources should target these disparities in income and race. Citation Format: Guettchina Telisnor, Alexander S. Lim, Zhongyue Zhang, XiangYang Lou, Ibrahim Nassour, Bo Han, Edward Agyare, Sherise C. Rogers. Impact of COVID-19 on pancreatic cancer outcomes in Florida [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A048.

Background Pancreatic Ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer mortality and is projected to increase in incidence by 2030 in the United States. Compared to Caucasians, African Americans (AA) have a significantly increased risk for PDAC, even after adjusting for risk factors (e.g., SES, obesity and smoking), and worse survival outcomes. Somatic and germline mutations are found in 90% and 10% PDAC cases, respectively. These mutations are known to alter the incidence and therapeutic response of PDAC, and studies show significant differences in genetic expression between AA and Caucasians. Our study focused on the current understanding of genetic mutations that influence the pharmacoethnicity of FDA approved PDAC drugs. Methods For this narrative review, multiple searches were generated from the PubMed database using several variations of the following keywords: pharmacogenetics, pancreatic cancer, race, ethnicity, African, Black, toxicity, and the FDA approved drug names: Fluoropyrimidines, Topoisomerase inhibitors, Gemcitabine, Nab-Paclitaxel, Platinum agents, Pembrolizumab, PARP-inhibitors, and NTRK fusion inhibitors. Names of genes were extracted from studies with established data on pharmacogenetic-related racial disparities. Additional studies were found from the cited section. After searches for PubMed was thoroughly reviewed, the same keywords were imputed in Web of Science. The University of Alabama at Birmingham (UALCAN) database was used to verify if overall survival was significant for the expression of the genes identified in literature. Only genes that were found in the literature and UALCAN database were included. Results The following genes were identified as influencing pharmacogenetic-related disparities and then assessed for significance in overall survival using the UALCAN database: CDA, TYMS, UGT1A1, SLC and ABCB transporters, BRCA 2, PALB2, ERCC1, ERCC2, NTRK 1-3, POLA2, and CY2C8. The following genes were not significant for overall survival: CDA, UGT1A1, PALB2, ERCC1, ECCR2, NTRK 1-3. TYMS (p=0.0052), POLA2 (p=0.022), CYP2C8 (p=0.027), BRCA2 (p=0.027) genes were significant for impacting overall survival outcomes. The UALCAN database has low sample size of African Americans (n=6) therefore, significance for overall survival based on race could not be properly stratified. Conclusion In conclusion, racial differences in gene expression can influence the therapeutic response of PDAC. The UALCAN database provides overall survival for patients with PDAC, but conclusions about race could not be properly stratified due to the low sample size of African Americans. As targeted therapy advancements improve, referrals for genetic testing should also because it can direct treatment course for avoiding toxicities and improving medical precision for AA. Citation Format: Guettchina Telisnor, Esther Frimpong, Edward Agyare, John M. Allen, Sherise C. Rogers. Pharmacogenetics of pancreatic ductal adenocarcinoma: A review of racial disparities [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr C026.

Introduction Pancreatic cancer (PC) portends a poor prognosis, is the current third-leading cause of cancer deaths in the United States, and is still rising. The state of Florida has the second-highest rate of new cases of PC within the United States with an incidence of 460/100,000. It is also a disease with significant disparities. African Americans with PC have a 50–90% increased incidence, lower rates of surgery, and worse overall mortality in comparison to other racial groups. With increased knowledge of these disparities in recent years, we sought out to identify whether these differences were present in the state of Florida by examining differences in pancreatic cancer survival outcomes between race, age, and income. Materials and Methods Patients with pancreatic adenocarcinoma diagnosed from January 1st, 2017 to October 31st, 2020 were identified through the statewide clinical research and network database called OneFlorida Clinical Consortium (OneFlorida) by using the ICD10 diagnosis code for pancreatic cancer. Patients with a diagnosis of neuroendocrine carcinoma were excluded. Patients were followed for at least one year unless a death occurred. Summary statistics were reported for demographic variables. The demographic variable for income was stratified by low being < $53,000 and high being ≥ $53,000. Kaplan-Meier analysis with log-rank test was performed to compare the difference in overall survival time among groups. Cox proportional hazards models were also fitted to test the between-group differences and compute the 95% confidence intervals of hazard ratio, while adjusting for informative covariate(s) when necessary. Results A total of 2,739 unique patients were available for analysis. The distribution of the sample was 68.7% White, 23.4% Black, and 7.9% Other. The median age was 67 years (27–89). There were 49.8% women and 50.2% men. The median income was $52,915 ($23,704–$124,821). Significant differences in overall survival were detected (p-values < 0.001) between age, income, and racial groups, but not between sex. Patients that were Black, >67 years old, and had low-income had a significantly less survival time than their corresponding contrasts independently. The mean survival (in days) for low income vs. high income was 779.5 vs. 945.9 (p<.0001). The differences remained significant in stratified analyses by cancer stage. In stage II PC, the mean survival (in days) for White vs. Black populations was 1134.9 days vs 472.2 days, and in stage IV PC the survival comparison was 770.2 days vs. 787.5 days between the same groups. Discussion Significant race, age and income disparities in survival exist in the state of Florida. These disparities are present even when stage is accounted for. Knowledge of health disparities statistics are not sufficient, and a targeted multi-stakeholder approach needs to be developed to improve survival outcomes of our patients. Limitations to this study include the racial demographic of “other” not having further description due to limited data availability through the clinical research network. Citation Format: Guettchina Telisnor, Alexander S. Lim, Zhongyue Zhang, XiangYang Lou, Ibrahim Nassour, Sherise C. Rogers. Pancreatic cancer survival disparities in Florida using a statewide database [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr A076.

667 Background: Pancreatic cancer (PDAC) is the third-leading cause of cancer death in the United States. Florida had a high infection rate with several peaks throughout 2020 and 2021. The first aim of this study is to evaluate the impact of the COVID-19 pandemic on survival time, rate of surgical resection, and time to treatment of newly diagnosed pancreatic cancer in Florida. The second aim was to assess whether disparities with respect to race, age, income, and gender were exacerbated in newly diagnosed pancreatic cancer via stratified analysis of pandemic groups. Methods: This retrospective study included patients identified by OneFlorida+ Clinical Research Network, a statewide data trust, who were newly diagnosed with pancreatic adenocarcinoma via ICD 10 coding from January 1st, 2017 to October 31st, 2020. Patients were compared between 3 cohorts based on date of pancreatic cancer diagnosis: pre-pandemic (01/01/2017- 09/30/2019), transition (10/01/2019-02/28/2020), and pandemic (03/1/2020-10/31/2020). Patients with a diagnosis of neuroendocrine carcinoma were excluded. Results: 934 unique patients were identified for analysis, of whom 81.3% were in the pre-pandemic cohort, 8.2% in the transition cohort, and 10.5% in the pandemic cohort. The racial distribution was 19.4% African American, 70.2% Caucasian, 0.7% Asian, 8.2% of Other races, and 1.3% reported unknown race or refused to answer. The median age was 67 years (range, 27–89 years). Gender was even. The median income was $52,915 (range, $23,704–$124,821). The differences in overall survival were not significant for age and gender across the 3 groups. Patients with income <$53,000 had significantly lower survival time across all groups. African Americans had significantly lower survival time in the pre-pandemic and transition cohort (p< .005), but Caucasians had the lowest survival time for the pandemic group (p <.005). 60.2% of early-stage patients did not have surgery and the group distribution was 64.2% pre-pandemic, 48.5% transition, and 44.4% pandemic (p< 0.027). Time to treatment was not significant across all groups and demographics. Conclusions: This study found a decrease in diagnosis, survival rate for some groups, and surgical resection rates during the COVID-19 pandemic in Florida. Resource planning should target these disparities in income and race.[Table: see text]